Search Results Search Sort by RelevanceMost Recent Case and Commentary Dec 2018 When Should Iatrogenic Polypharmacy Be Considered a Disease? Christine Wieseler, PhD When symptoms of polypharmacy are consistent with those of difficult-to-diagnose disorders, reliable determinations about which drugs are necessary is critical. AMA J Ethics. 2018;20(12):E1133-1138. doi: 10.1001/amajethics.2018.1133. Personal Narrative Jul 2021 The Importance of Listening in Treating Invisible Illness and Long-Haul COVID-19 Dorothy Wall, MA Overly physicalist approaches to caring for patients are not likely to help them. AMA J Ethics. 2021;23(7):E590-595. doi: 10.1001/amajethics.2021.590.
Case and Commentary Dec 2018 When Should Iatrogenic Polypharmacy Be Considered a Disease? Christine Wieseler, PhD When symptoms of polypharmacy are consistent with those of difficult-to-diagnose disorders, reliable determinations about which drugs are necessary is critical. AMA J Ethics. 2018;20(12):E1133-1138. doi: 10.1001/amajethics.2018.1133.
Personal Narrative Jul 2021 The Importance of Listening in Treating Invisible Illness and Long-Haul COVID-19 Dorothy Wall, MA Overly physicalist approaches to caring for patients are not likely to help them. AMA J Ethics. 2021;23(7):E590-595. doi: 10.1001/amajethics.2021.590.